Long-Term Immunological Alertness and Response to COVID-19 Vaccination-Conditions for Prevention in Early Palliative Oncological Care Patients.

Publication date: Mar 13, 2024

Aside from the general population, the COVID-19 pandemic has also affected a group of patients in palliative oncology care. In this study, long-term immune responses against SARS-CoV-2 after vaccination were monitored in a cohort of patients in palliative oncology care. This non-randomized, prospective, and open-label pilot study recruited patients from the Palliative Oncology Program and included 147 patients, of which 80 were females (54. 4%) and 67 males (45. 6%). The overall evaluation included current health status, SARS-CoV-2 anti-S IgG titer, and neutralizing antibodies using the SARS-CoV-2 virus neutralization test (VNT). Anti-S IgG antibody analysis revealed high (H) antibody levels in 35. 7% (n = 10) and very high (VH) levels in 39. 3% (n = 11) of patients after the second vaccination dose. Similarly, after the third dose, H was found in 29. 6% (n = 32) and VH in 55. 5% (n = 60) of patients. High and very high anti-S IgG antibody levels were consistent with high VNT titers (>2560) and H antibody levels in 17. 1% (n = 12) or VH in 82. 9% (n = 58) of patients. Patients with two or more doses showed H and VH antibody levels at a median of 451 and 342 days after vaccination, respectively. In this clinical trial, patients showed high and very high levels of anti-S IgG antibodies over a longer period of time. These patients did not show reduced immunological responses to the COVID-19 vaccine challenge. We can assume that prevention through vaccination can reduce the risk of complications or death from COVID-19 in patients in early palliative oncology care.

Open Access PDF

Concepts Keywords
Basel anti-S IgG
Pandemic COVID-19 vaccine
Pilot inpatient care
Vaccination palliative oncological care
VNT

Semantics

Type Source Name
disease MESH COVID-19
disease VO vaccination
disease VO population
disease VO titer
disease VO vaccination dose
disease VO dose
disease VO time
disease VO COVID-19 vaccine
disease MESH complications
disease MESH death
disease VO vaccine
disease MESH cancer
pathway REACTOME Immune System
disease MESH infection
drug DRUGBANK Coenzyme M
disease VO organization
disease MESH cytokine storm
disease MESH viral infections
disease IDO production
disease MESH seroconversion
disease MESH reinfection
disease IDO history
disease IDO blood
disease MESH breakthrough infection
disease MESH morbidity
disease IDO immune response
disease VO vaccine dose
disease MESH infectious diseases
disease MESH influenza
disease MESH tetanus
disease MESH hepatitis
disease MESH metastases
disease VO stomach
disease VO manufacturer
disease VO USA
disease VO device
disease IDO assay
disease IDO facility
drug DRUGBANK Aspartame
disease VO volume
disease VO antibody titer
disease VO vaccinated
disease VO Comirnaty
disease VO vaccination frequency
disease VO effectiveness
disease IDO immunosuppression
drug DRUGBANK Sulfasalazine
disease VO Pal
disease VO protocol
disease MESH lymphadenopathy
disease VO unvaccinated

Original Article

(Visited 1 times, 1 visits today)